Samsara receives USD 3.2 million seed funding

20th December 2019 – Samsara Therapeutics Inc, a biotechnology startup with the world’s largest platform for the discovery and development of drugs to activate autophagy, announced the completion of their USD 3.2 million seed round. After the initial pre-seed investment of an undisclosed amount by Apollo Health Ventures at the end of 2018, to achieve rapid advances in the development of its early drug candidates and top-class filling of key positions, Samsara was able to attract a group of additional investors including firms like Cambrian BioPharma and Kite Ventures, as well as business angels such as Bruce Barclay, board member of the Buck Institute for Research on Aging in California, USA, Kent Wakeford and Eric Boyle, Managing Director at Qatalyst Partners.